Prevalence, clinical significance, and persistence of autoantibodies in COVID-19

• DOI: 10.1186/s12985-023-02191-z
• Publication Date: 2023-10-16T11:02:57Z
• Authors: Se Ju Lee; Taejun Yoon; Jang Woo Ha; Jinnam Kim; Ki Hyun Lee; Jung Ah Lee; Chang Hyup Kim; Sang-Won Lee; Jung Ho Kim; Jin Young Ahn; Nam Su Ku; Jun Yong Choi; Joon-Sup Yeom; Su Jin Jeong
• Keywords: Clinical Significance

Interest in complications and sequelae following Coronavirus disease 2019 (COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune diseases the association between autoantibodies severity of COVID-19. Thromboembolic are frequent patients with COVID-19, anti-phospholipid antibodies (aPL) frequently detected. We conducted this study to investigate prevalence, clinical significance, persistence anti-nuclear (ANA) aPLs COVID-19.We enrolled diagnosed COVID-19 oxygen demand admitted a tertiary hospital South Korea July 2020 March 2022. ANA levels were assessed using an immunoassay kit.A total 248 study. Among them, five ANA-positive, 41 aPL-positive (IgM anti-cardiolipin (aCL) antibody seven patients, IgG aCL IgM anti-β2Glycoprotein1 (aβ2-GPI) 32 aβ2-GPI one patient). Two ANA-positive 13 aβ2-GPI-positive 5 7 aCL-positive 2 eligible for follow-up analysis, 100%, 69.2%, 40%, 50% remained autoantibody-positive, respectively. There no differences outcomes autoantibody-positive autoantibody-negative groups, except group showing tendency worse outcomes.A significant proportion persisted several months after symptom onset. Whether these related long-term requires further investigation.